Brady, Kristine G., Thomas J. Kelley, and Mitchell L. Drumm. Examining basal chloride transport using the nasal potential difference response in a murine model. Am J Physiol Lung Cell Mol Physiol 281: L1173-L1179, 2001.-Epithelia of humans and mice with cystic fibrosis are unable to secrete chloride in response to a chloride gradient or to cAMP-elevating agents. Bioelectrical properties measured using the nasal transepithelial potential difference (TEPD) assay are believed to reflect these cystic fibrosis transmembrane conductance regulator (CFTR)-dependent chloride transport defects. Although the response to forskolin is CFTR mediated, the mechanisms responsible for the response to a chloride gradient are unknown. TEPD measurements performed on inbred mice were used to compare the responses to low chloride and forskolin in vivo. Both responses show little correlation between or within inbred strains of mice, suggesting they are mediated through partially distinct mechanisms. In addition, these responses were assayed in the presence of several chloride channel inhibitors, including DIDS, diphenylamine-2-carboxylate, glibenclamide, and 5-nitro-2-(3-phenylpropylamino)-benzoic acid, and a protein kinase A inhibitor, the Rp diastereomer of adenosine 3Ј,5Ј-cyclic monophosphothioate (Rp-cAMPS). The responses to low chloride and forskolin demonstrate significantly different pharmacological profiles to both DIDS and Rp-cAMPS, indicating that channels in addition to CFTR contribute to the low chloride response. cystic fibrosis; cystic fibrosis transmembrane conductance regulator; ion channel inhibitors; protein kinase A CYSTIC FIBROSIS (CF) is an autosomal recessive disorder caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR; see Refs. 17, 25, 26) . CFTR can function as a cAMPregulated chloride channel (2, 3 ) and also appears to affect the function of other ion channels, including the epithelial sodium channel (12, 33) , the outward rectifying chloride channel (ORCC; see Refs. 7 and 27) , and the renal inward rectifying potassium channel (22) . Most of the characterization of CFTR as an ion channel or regulator of other channels has been restricted to cell lines and heterologous expression systems in part because of the limitations of in vivo assays. An exception is utilization of the transepithelial potential difference (TEPD) measurement in vivo as a means to monitor electrophysiological changes across an intact tissue.
The nasal TEPD measurement was originally described (18, 19) as a means to discriminate between CF and non-CF individuals based on bioelectrical potential difference (PD) properties that differ between the two groups. With the use of this assay, it was observed that the unstimulated basal PD measurement is hyperpolarized to a greater degree in CF compared with non-CF tissue. This difference was shown to be predominantly the result of amiloride-sensitive sodium absorption. In the presence of amiloride, the PD can be hyperpolarized by imposing a chloride gradient on the epithelium such that the luminal chloride concentration is low relative to the serosal fluid. The PD can be further hyperpolarized by stimulation with agents that raise cAMP levels. Both of these hyperpolarizing responses are absent or dramatically reduced in CF (20) , indicating that they are CFTR dependent at some level.
It has been inferred from in vitro experiments that the chloride permeability increase that occurs in response to increased cAMP levels is the result of activation of CFTR channels (6, 24) . However, the mechanism responsible for the hyperpolarization in response to a chloride gradient is more questionable. A reasonable hypothesis is that the low chloride response reflects the basal level of CFTR activity. Unfortunately, genetic and nongenetic heterogeneity in humans makes characterization of factors involved in the electrophysiological gradients measured by the PD difficult. However, with slight modification, this assay can be applied to the mouse (8-10, 14-16, 23, 29, 30, 32) in which both types of heterogeneity can be minimized. We have found that the assay is very reproducible when animals are maintained in a consistent manner and matched for age and gender when assayed (unpublished observations). Our aim in using the PD assay with a mouse model is to investigate the mechanisms responsible for the low chloride response. Because this response is absent in patients with CF, understanding its physiological basis may aid in a greater understand-ing of the pathophysiology in CF. If channels other than CFTR are involved, their identification could potentially provide additional therapeutic targets.
MATERIALS AND METHODS
Animals. Female mice of the A/J, C57BL/6J, DBA/2J, BALB/cJ, C3H/HeJ, and 129/SvEms-ϩTer?/J strains were obtained from Jackson Laboratory (Bar Harbor, ME). Mice with the Cftr mutation ⌬F508 on a mixed 129/SvEv and C57BL/6J background (37) were a generous gift from Dr. Kirk Thomas at the University of Utah School of Medicine. As noted, in some experiments, mice used had the ⌬F508 mutation backcrossed onto the C57BL/6J background. Experiments were performed when the mice were between 12 and 31 wk of age. The project was approved by the Case Western Reserve University Institutional Animal Care and Use Committee.
Nasal PD measurements. The PD across the nasal epithelium of the mice was measured according to procedures previously described elsewhere (11, 16) , with some modifications. Briefly, mice were anesthetized with 11 mg/ml ketamine, 2 mg/ml xylazine, and 0.4 mg/ml acepromazine in PBS. Animals were dosed intramuscularly with ϳ0.003 ml/g mouse weight for baseline measurements and 0.0075 ml/g for the assay in the presence of pharmacological agents requiring longer periods of anesthesia. A PE-10 tube stretched to one-half the original diameter was inserted 2 mm into the mouse nostril and placed against the septum. With the use of a syringe pump (model A-99; Razel Scientific Instruments) and 3-ml syringes, Ringer solution warmed to 37°C was perfused into the nostril at a rate of ϳ7 l/min. Valves controlled which solution entered the nostril, with a 30-s delay until the new solution reached the nasal epithelium. Readings were taken until a steady-state value was reached before perfusing the nasal epithelium with a new solution. Filter paper wicks were used to absorb excess liquid from the mouth and opposite nostril of the mouse being tested. Bridges (4% agar) connected the tubing to calomel electrodes, and each bridge was made in the same solution as the perfusate it measured (HEPES-buffered Ringer or chloridefree HEPES-buffered Ringer). A needle containing 4% agar in HEPES-buffered Ringer was placed subcutaneously in the mouse's back and connected to another calomel electrode to serve as a reference. The measuring and reference calomel electrodes were situated in a KCl bath in which one end of the agar bridge was also immersed. The other end of the measuring electrode's bridge was in contact with the perfusate, ϳ20 cm from the mouse nose. The transepithelial difference was measured with a voltmeter (model ISO-DAM-D; World Precision Instruments), and the signal was recorded on a chart recorder (model BD112; Kipp and Zonen). Solution resistance from the measuring electrode's agar bridge to the mouse nose was calculated to be ϳ1.2 ϫ 10 6 ⍀, whereas input resistance of the amplifier was Ͼ10 12 ⍀. The PD measurements were not corrected for junction potentials, and changes in PD values were calculated by subtracting the final steadystate value from the first value taken after switching solutions. Before measurements, the system was zeroed by adjusting the voltmeter after connecting the reference needle to the tube normally placed in the mouse nose to complete the circuit.
Solutions and drugs. The Ringer solutions used to perfuse the nasal epithelium included HEPES-buffered Ringer with (in mM) 10 HEPES, pH 7.4, 138 NaCl, 5 KCl, 5 Na 2HPO4, 1.8 CaCl2, and 1 MgSO4 and chloride-free HEPES-buffered Ringer with (in mM) 10 HEPES, pH 7.4, 138 sodium gluconate, 5 potassium gluconate, 2.5 Na 2HPO4, 3.6 hemicalcium gluconate, and 0. M; Calbiochem), 5-nitro-2-(3-phenylpropylamino)benzoic acid (NPPB; 10 Ϫ4 M; Calbiochem), DIDS (5 ϫ 10 Ϫ4 M; Calbiochem), diphenylamine-2-carboxylate (DPC; 10 Ϫ3 M; RBI, Natick, MA), and the Rp diastereomer of adenosine 3Ј,5Ј-cyclic monophosphothioate (Rp-cAMPS; 10 Ϫ4 M; BioLog, La Jolla, CA). Except for forskolin, stock solutions of the drugs were prepared on the day of the experiment.
Statistics. Data are presented as means Ϯ SE. If an individual mouse was tested multiple times, the data were averaged and presented as a single data point in the group mean. Statistics were performed using Statview (versions 4.5 and 5.0; SAS Institute, Cary, NC) using either an unpaired Student's t-test, ANOVA followed by Dunnett's post hoc test, or Fisher's r-to-z covariance analysis as indicated. P Ͻ 0.05 was considered statistically significant.
RESULTS

Effect of CFTR(⌬F508/⌬F508) mutation on the nasal TEPD.
The TEPD measurement predominantly reflects the level of sodium and chloride transport across the airway epithelium in vivo. For this work, the TEPD assay was separated into two separate traces to increase mouse survival. First, a baseline TEPD was measured while the epithelium was perfused with an isotonic Ringer solution until a stable value was determined. A second trace was made up of three distinct phases. Initially, amiloride-sensitive sodium absorption was inhibited by perfusion with Ringer solution containing amiloride. Once a steady-state value was reached, a chloride gradient was created across the epithelium by perfusion with chloride-free Ringer solution in which chloride ions were replaced with impermeant gluconate ions to stimulate chloride secretion into the lumen. Once a new steady state was reached and the change in potential difference (⌬TEPD) was determined, forskolin was added to the chloride-free Ringer solution to stimulate adenylate cyclase and raise cAMP. The response to cAMP was measured again until a steady state was reached, and the ⌬TEPD was determined again.
CF mouse models, including the Cftr ⌬F508 mice, exhibited consistent ion transport characteristics similar to those seen in human CF patients (11, 31) . The differences between Cftr(⌬F508/⌬F508) mice and their wild-type siblings are shown in Fig. 1 and are summarized in Table 1 . The average baseline TEPD in isotonic Ringer solution of CF mice was significantly more negative than that of wild-type siblings because of the increased sodium absorption seen in CF mice (non-CF: Ϫ11.1 Ϯ 0.4 mV and CF: Ϫ32.7 Ϯ 1.2 mV, P Ͻ 0.0001). The addition of amiloride to the Ringer solution inhibited epithelial sodium transport, causing a depolarization in the PD in both CF and wild-type mice. However, the average amiloride baseline measured in CF mice was still significantly more negative than that of wildtype siblings (non-CF: Ϫ3.4 Ϯ 0.3 mV and CF: Ϫ10.6 Ϯ 0.5 mV, P Ͻ 0.0001).
With the addition of chloride-free Ringer solution, we consistently saw a predicted junction potential of approximately Ϫ12 mV because of the difference in ion composition between the chloride-free solution perfusing the nostril and the isotonic solution used in the reference bridge. In calculating the low chloride response, the initial value used was the peak of the junction potential. The ⌬TEPD in response to chloridefree solution was also significantly different between wild-type and CF mice (P Ͻ 0.0001). In wild-type mice, perfusion of the nasal epithelium with chloride-free solution caused a hyperpolarization (⌬TEPD ϭ Ϫ15.8 Ϯ 1.0 mV). In contrast, the TEPD measured in CF mice became more depolarized in response to the chloride-free solution (⌬TEPD ϭ 1.7 Ϯ 0.8 mV). As seen in Fig. 1 , a similar trend was observed in mixed C57/129 mice when forskolin was added to the chloride-free Ringer solution to stimulate chloride secretion by increasing the cAMP level. However, the same phenomenon was not observed with ⌬F508/⌬F508 mice congenic on the C57BL/6J background and their non-CF littermates (Table 1) . Here the forskolin responses were lower in the wild-type mice, resulting in no significant (P ϭ 0.1420) difference between CF and wild-type mice. The differences in the forskolin response caused by the genetic background are seen consistently (data not shown) and are being pursued further.
The nasal TEPD chloride-free and forskolin responses show little correlation. The lack of chloride transport in CF in response to low chloride challenge or to stimulation by forskolin suggested that both transport mechanisms may occur through CFTR. It has been suggested that, in non-CF humans, the hyperpolarization that occurs in response to a chloride gradient is the result of basal levels of chloride secretion and that the hyperpolarization with the further addition of isoproterenol is a result of stimulated chloride secretion, both occurring through CFTR (20) . Therefore, it was hypothesized that because of limiting amounts of CFTR and its regulatory compounds, a larger CFTR basal chloride response would result in a reduced CFTRstimulated chloride response and vice versa.
We tested this hypothesis in mice by comparing the changes in PD caused by chloride-free Ringer solution and those caused by the further addition of forskolin to Fig. 1 . Transepithelial nasal potential difference traces from a wildtype (A) and a ⌬F508/⌬F508 cystic fibrosis (CF; B) mouse on the original mixed 129/SvEvs and C57BL/6J genetic background. Time 0, perfusion with Ringer solution and amiloride. The junction potential marks the switch to chloride-free Ringer solution containing amiloride followed by the switch to chloride-free HEPES-buffered Ringer (HBR) containing amiloride and forskolin as indicated. TEPD, transepithelial potential difference. C: recording in which a bath of HBR was substituted for the mouse. Trace shows that the junction potential is a consistent function of the circuitry and that the potential difference is stable after the perfusate was changed to chloride-free HBR. stimulate CFTR chloride secretion. We found no correlation for the two responses between several inbred strains (Fig. 2) or within an individual inbred strain (Fig. 3) . We found that the forskolin response measured in six inbred strains of mice varies little between the strains. This contrasts with large variations in the low chloride response measured in the same strains (Fig. 2) . Specifically, the C57BL/6J strain had the most negative low chloride response (⌬TEPD ϭ Ϫ16.5 Ϯ 0.6 mV), whereas the A/J strain had the least negative low chloride response (⌬TEPD ϭ Ϫ4.8 Ϯ 0.8 mV) of the strains tested, and yet their forskolin responses were nearly identical (⌬TEPD: C57BL/6J, Ϫ2.5 Ϯ 1.1 mV and A/J, Ϫ2.6 Ϯ 0.8 mV). Even within a single inbred strain, in this case C57BL/6J, there was little correlation between low chloride and forskolin responses, as seen in Fig. 3 .
Effect of chloride channel inhibitors on the chloridefree and forskolin responses. The lack of correlation between the low chloride and forskolin responses raised the possibility that the low chloride response may involve channels other than CFTR. To test this possibility further, we examined the effect of several chloride channel inhibitors that have been characterized as to their effect on CFTR on the low chloride and forskolin responses in C57BL/6J mice. Figure 4 shows the effect of DPC, which is known to inhibit CFTR and other chloride channels (4, 21, 35, 36, 38) , and DIDS, which is known to inhibit chloride channels other than CFTR (5, 13, 28, 35) . DIDS and DPC have little effect on the response to a low chloride gradient compared with that in control mice, as shown in Fig. 4A (⌬TEPD ϭ Ϫ19.5 mV for control, Ϫ17.5 mV for DPC, and Ϫ17.5 mV for DIDS). In contrast, DIDS and DPC had the expected results on the forskolin response (Fig.   4B ), presumed to be mediated by CFTR. DPC reduced the forskolin response to Ϫ1.9 mV compared with the control (⌬TEPD ϭ Ϫ7.0 mV), whereas DIDS (⌬TEPD ϭ Ϫ7.0 mV) had little effect. Figure 4C summarizes the effects of DIDS, DPC, and several additional chloride channel inhibitors. Although none of the chloride channel inhibitors eliminate the low chloride response, both glibenclamide and the combination of DIDS and DPC did significantly (⌬TEPD: glibenclamide ϭ Ϫ11.0 Ϯ 1.1 mV and DIDS ϩ DPC ϭ Ϫ10.0 Ϯ 2.2 mV vs. control ϭ Ϫ19.4 Ϯ 0.9 mV; P Յ 0.01) reduce the low chloride response. These same compounds eliminated the forskolin response (⌬TEPD: glibenclamide ϭ 0.2 Ϯ 0.9 mV; P Յ 0.01; DIDS ϩ DPC ϭ 0.1 Ϯ0.8 mV; P Յ 0.05 vs. control ϭ Ϫ5.9ϩ1.3 mV). Additionally, DPC significantly (⌬TEPD ϭ Ϫ1.4 Ϯ1.0 mV; P Յ 0.05) reduced the forskolin response.
Effect of a protein kinase A inhibitor, Rp-cAMPS, on the chloride-free and forskolin responses.
CFTR is regulated by cAMP-dependent phosphorylation and by intracellular ATP (1). By inhibiting protein kinase A (PKA) with Rp-cAMPS, we investigated the effect of acute PKA inhibition on both the low chloride and forskolin responses. Figure 5 demonstrates that inhibiting PKA eliminates the forskolin response (⌬TEPD ϭ Ϫ6.8 Ϯ 1.6 mV for control and Ϫ0.4 Ϯ 1.4 mV for Rp-cAMPS, P ϭ 0.015). In contrast, Rp-cAMPS had no significant effect on the response to low chloride challenge (⌬TEPD ϭ Ϫ18.4 Ϯ 1.4 mV for control and Ϫ17.4 Ϯ 1.7 mV for Rp-cAMPS). There was no effect of Rp-cAMPS on the low chloride response when the duration of low chloride exposure was extended (data not shown), suggesting the lack of effect is not an issue of drug access to the cell. Values were calculated after reaching a steady state in the presence of chloride-free Ringer solution and chloride-free Ringer solution containing forskolin (n ϭ 8-10 mice/experiment). Values shown are mean change (⌬) in TEPD Ϯ SE. Amiloride was present in both solutions. Mice were exposed to Ringer solution containing amiloride until a steady state was reached before the switch to chloride-free Ringer solution. Fig. 3 . Correlation of chloride-free and forskolin transepithelial nasal potential difference values from the C57BL/6J strain. Values represent individual mouse ⌬TEPD measurements calculated after reaching a steady state in the presence of chloride-free Ringer solution followed by a steady state in chloride-free Ringer solution containing forskolin (n ϭ 26 mice). Amiloride was present in both solutions. Mice were exposed to Ringer solution containing amiloride until a steady state was reached before the switch to chloride-free Ringer solution. Solid line represents the mean, and dotted lines represent the 95% confidence interval for the mean (R 2 ϭ 0.27, P ϭ 0.4297 by Fisher's r-to-z covariance analysis).
DISCUSSION
The absence or reduction of functional CFTR is clearly the fundamental defect in CF. However, it is not clear how this deficit is involved in the pathophysiology of the disease. Loss of CFTR results in a failure of the airway epithelium to secrete chloride not only in response to cAMP but also in response to a chloride gradient. Concomitantly, there is an increase in sodium absorption across the airway epithelium. The loss of response to cAMP appears to be the result of the loss of both CFTR and a channel (ORCC) whose physiological role is unknown, at least in some airway cells. The ORCC activity appears to be distinct from CFTR in channel pharmacology as well as in activation and conductance properties. It is nonetheless CFTR dependent, since CF airway cells heterologously expressing functional CFTR display ORCC activity in response to cAMP (27) . Fig. 4 . Effect of a panel of chloride channel inhibitors on the chloride-free and forskolin transepithelial nasal potential difference responses of C57BL/6J mice. Mice were assayed for a chloride-free response (A) and forskolin response (B) in the presence of diphenylamine-2-carboxylate (DPC) or DIDS and in the absence of either chloride channel blocker. Traces shown are averages Ϯ SE of data taken at 30-s intervals. ⌬TEPD at the final 30-s time point in the presence of chloride-free Ringer solution with amiloride was Ϫ19.5 mV for control (n ϭ 17), Ϫ17.5 mV for DPC (n ϭ 13), and Ϫ17.5 mV for DIDS (n ϭ 11). ⌬TEPD in the presence of chloride-free Ringer solution with amiloride and forskolin was Ϫ7.0 mV for control (n ϭ 17), Ϫ1.9 mV for DPC (n ϭ 12), and Ϫ7.0 mV for DIDS (n ϭ 10). Mice were pretreated with the appropriate channel blocker in Ringer solution containing amiloride for at least 2 min before the switch to chloride-free Ringer solution (time 0, A) and the further switch to include forskolin (time 0, B). C: summary of changes in the ⌬TEPD for the chloride-free response (filled bars) and the forskolin response (open bars) induced by chloride channel blockers. Bars represent the mean ⌬TEPD, and error bars represent the SE. The number of mice tested is shown above the bar. One mouse did not survive the procedure and could not be included in the forskolin, DIDS, and DPC treatment. NPPB, 5-nitro-2-(3-phenylpropylamino)benzoic acid. *P Ͻ 0.05 and **P Ͻ 0.01 vs. control by ANOVA followed by Dunnett's post hoc test. The chloride-free response, also absent from CF epithelia, is clearly CFTR dependent at some level. The mechanism responsible for this basal conductance has not been identified. A reasonable assumption would be that it represents basally active CFTR, possibly because of resting levels of cAMP and PKA activities. In human nasal TEPD studies, it is the combination of the low chloride and cAMP-stimulated responses that discriminates between CF and non-CF individuals, leading to the postulation that the responses reflect two activity states of CFTR, a basal state and a stimulated state (20) . If so, one might predict an inverse relationship between the two responses.
The results presented here show that the chloridefree and cAMP responses are distinct. Our murine studies found a lack of correlation between the chloride-free and cAMP-stimulated responses either within or between inbred strains of mice. Additionally, we found that each response had a characteristic pharmacology both to a panel of chloride channel inhibitors and to a PKA inhibitor that differentiated the two responses. Although it cannot be excluded that there are channel activities common to both responses, there must be activities distinct to each. This suggests that the response to low chloride challenge may reflect channels or regulatory processes that are CFTR dependent, analogous to the ORCC properties of single cells, where CFTR is required for an ORCC-mediated chloride conductance, but neither channel is the sole carrier of the apical epithelial chloride conductance.
In trying to identify the mechanism involved in the low chloride response, we have attempted to reconcile with data on known channels. A caveat to that approach is that most channels are characterized at the channel or cell level to remove the complexities of intact tissue from the analysis. Tarran et al. (34) have shown that, even within ciliated cells of mouse nasal epithelium, there are at least two cell types with regard to unstimulated chloride transport. When one considers that there are even more epithelial cell types and that some ion permeation occurs paracellularly, the intact epithelium is certain to display characteristics not found in cultured or individual primary cells. So, although the TEPD assay is limited in the detail with which electrophysiological responses can be described, it does allow for the intact epithelium to be monitored in vivo.
We propose that the simplest and most consistent explanation of our data is that the low chloride response is transcellular and involves channels distinct from CFTR. Furthermore, the same response is virtually absent in CF mice, establishing a requirement of the low chloride response for CFTR. Although the nature of the requirement for CFTR in the chloride-free response is unclear, we can propose several modes of interaction. It is possible that CFTR may dimerize with other chloride channels such that mutations in CFTR alter chloride transport through these partner channel(s). Alternatively, the observation that different subsets of airway epithelial cells express different chloride conductances raises the possibility that the stoichiometry of cell types is altered in CF and the proportion of cell types responsible for the chloride-free response are reduced or absent in CF mice. Finally, CFTR may play a role in regulating signaling in cells of the epithelium, or its lack may trigger signals that downregulate the low chloride participants. Previous studies support this last possibility. We have shown that nitric oxide synthase-2 levels are decreased in CF airway epithelia (32) . Furthermore, we have demonstrated that decreasing nitric oxide synthase-2 activity either acutely by pharmacological means or constitutively by knocking out the Nos2 gene reduces the chloride-free response to levels observed in CF mice (8) . The causal link between reduced CFTR and nitric oxide synthase-2 is not clear but could explain the CFTR dependence of the low chloride response as one of the aberrant signaling processes. These and other possibilities need to be explored further.
The difference in the low chloride response observed between several inbred mouse strains in this study permits the genetic dissection of the low chloride response. Studies are thus currently underway to genetically identify the regulatory mechanisms responsible for the low chloride response. Regardless of the mechanism, if ion transport is contributing to the pathophysiology in CF patients, there is no reason to expect any one of the processes, lack of cAMP response, lack of low chloride response, or increased sodium absorption, to be more important than the other. Consequently, we need to better understand each of the processes so that they can be manipulated singularly and jointly to determine their relative roles in the disease process.
